UnitedHealth cuts asthma drug co-pay

In an attempt to keep patients taking their drugs, UnitedHealthcare has cut the co-payment for a group of asthma inhalers. This is not a new strategy for the health plan, which previously moved branded test strips and insulin products for diabetes into its lowest co-payment tier. This time the insurer's pharmacy benefit manager, UnitedHealth Pharmaceutical Solutions, has slashed the co-payment chlorofluorocarbon-free asthma drugs like Xopenex to its lowest tier, leaving patients to bear only $5 to $10 costs. CFC-free products are becoming central to medical practice, as CFC-emitting inhalers are considered an environmental risk. However, CFC-free products cost more, and are in short supply, which would normally increase their co-pay level. 

To learn more about UnitedHealthcare's co-payment strategy:
- read this United Press International piece
- read this Hub Magazine article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.